Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2011 Sep 3;127(3-5):262–268. doi: 10.1016/j.jsbmb.2011.08.011

Fig. 1. Cross-regulation of ER-α36 and HER2 expression in ER-negative breast cancer SK-BR-3 cells.

Fig. 1

(A). Western blot analysis of ER-α36 and HER2 expression in different breast cancer cell lines and mammary epithelial MCF10A cells. (B). Knock-down of ER-α36 expression down-regulated HER2 expression. RT-PCR and Western blot analysis of parental SK-BR-3 cells (SK-BR-3/P), SK-BR-3 cells transfected with an empty vector (SK-BR-3/V), with a control vector expressing shRNA for luciferase (SK-BR-3/L) and with the ER-α36 shRNA (SK-BR-3/36S). (C). SK-BR-3/V and SK-BR-3/36S cells treated with E2 (1nM) for different time points were assessed with Western blot analysis using phosphorylation specific or non specific anti-ERK1/2 antibodies. SK-BR-3/36S cells treated with EGF (20ng/ml) were included as a positive control. (D). SK-BR-3/P, SK-BR-3/V and SK-BR-3/36S cells were counted every other days for six days. Three dishes were used for each time points, the experiments were repeated three times and the data represent the mean ± s.e.